Key Development
According to official performance reports released on August 4, 2026, by the Drug Administration of Vietnam (DAV), Ministry of Health, national health authorities have achieved a key milestone in regulatory modernization: The total volume of administrative procedures and licensing workflows across the pharmaceutical and cosmetics sectors has been reduced to 75 procedures—representing a ~40% reduction compared to the baseline of 124 procedures enforced in prior years.
Regulatory Allocation & Decentralization Roadmap:
-
Current Administrative Split: Of the remaining 75 administrative procedures, 50 procedures are managed directly at the central level (DAV – Ministry of Health), while 25 procedures have been fully decentralized to provincial Departments of Health.
-
Decentralization Roadmap Through 2027: Effective January 1, 2027, the Ministry of Health will expand local authority by decentralizing an additional 16 administrative procedures to provincial health authorities.
-
Digital Public Services Integration: The MOH currently operates 47 digital public services within the pharmaceutical/cosmetic sector (encompassing 37 end-to-end full-process digital services and 24 services connected to the National Single Window portal).
Why It Matters
-
Eliminating Paper-Based Submission Bottlenecks: Since July 2023, 100% of applications for new registrations, renewals, and amendments for drug marketing authorizations and Active Pharmaceutical Ingredients (APIs) have transitioned to online platforms. This shift eliminated physical queuing at DAV headquarters.
-
Real-Time “Red Alert” Delay Tracking: The digitized management system automatically triggers real-time “red alerts” when application processing exceeds statutory timelines, identifying specific evaluation units responsible for delays. This enables immediate executive intervention while allowing biopharma enterprises to transparently track the evaluation process.
-
Accelerating Patient Access to Innovative Medicines: Streamlining administrative workflows supports a commercial database of over 24,000 valid drug marketing authorizations. Throughout 2025–2026, accelerated licensing and renewals enabled early market entry for next-generation vaccines, biologics, and targeted therapies across oncology, cardiology, and rare diseases.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, slashing administrative procedures by 40% and expanding provincial decentralization represents National Pharmaceutical Supply Chain Optimization.
Historically, processing backlogs for marketing authorization renewals created supply challenges for pharmaceutical enterprises and public hospital procurement boards. Implementing a three-pillar regulatory reform—Reducing Administrative Barriers $\rightarrow$ Full-End Digitization $\rightarrow$ Provincial Decentralization—delivers core strategic advantages:
-
Unburdening Central Regulatory Capacity: Transferring 25 procedures (and an additional 16 by 2027) to provincial Health Departments allows the central Drug Administration to focus resources on macro-policy formulation, cGMP facility audits, and post-market pharmacovigilance.
-
Institutionalizing Transparent Review Accountability: Enabling biopharma companies to monitor evaluation timelines via digital dashboards reduces informal compliance costs and eliminates bureaucratic friction.
Optimizing administrative efficiency directly impacts clinical outcomes. Reducing evaluation timelines accelerates the delivery of critical oncology regimens, rare disease biologics, and essential vaccines to hospital procurement networks nationwide throughout 2026.
Market Implications
-
Enhancing FDI Attractiveness in Biopharma: Transparent regulatory frameworks and shortened drug registration timelines encourage multinational pharmaceutical corporations (Big Pharma) to expand local marketing authorizations and technology transfer agreements in Vietnam.
-
Upgrading Provincial Health Department Governance Capacity: Absorbing 16 additional administrative procedures by 2027 requires regional Health Departments (particularly in HCMC, Hanoi, Dong Nai, and Binh Duong) to upgrade IT infrastructure and evaluation staff.
-
Streamlining Domestic & Imported Cosmetics Commercialization: Decentralizing cosmetic notification filings enables compliant manufacturers and importers to bring new SKUs to market efficiently, enhancing competitiveness against uncertified products.
Progress Matrix: Pharmaceutical & Cosmetic Administrative Reform
| Reform Metric | Recorded Benchmark (August 2026) | Strategic Trajectory & Market Impact |
| Total Active Procedures | 75 Procedures (~40% reduction from 124) | Eliminates redundant administrative layers & paperwork. |
| Provincial Decentralization | 25 / 75 Procedures (Currently decentralized) | Managed by regional Health Depts; unburdening central authorities. |
| 2027 Target Expansion | +16 Additional Procedures (By Jan 1, 2027) | Maximize local operational autonomy across all provinces. |
| Digital Public Services | 47 Services (37 full-process, 24 single-window) | Paperless processing; 100% online application & outcome delivery. |
| System Audit Controls | Automated “Red Alert” delay tracking | Enables real-time applicant tracking of evaluation steps. |
| Active Drug Authorizations | > 24,000 active licenses maintained | Secures supply for oncology, cardiac care & vaccines. |